The outbreak of the coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 that has created huge trepidation worldwide, has a mortality rate of 0.5% to 1% and is growing incessantly. There are currently no therapies and/or vaccines that may help abate this viral disease, but the use of masks and social distancing can limit the spread. Boosting immunity has been a simple way to resist viral infection and limit fatalities. In this context, the use of nutraceuticals appears to be a potential panacea. The ability of algae-based nutraceuticals, mainly Spirulina, to boost immunity against viral diseases has already been reported clinically. Spirulina-based nutraceuticals boost the adaptive and innate immunity, and bioactive compounds, such as angiotensin-converting enzyme (ACE) inhibitor peptides, phycobiliproteins, sulfated polysaccharides, and calcium-Spirulan, can serve as antiviral agents. The presence of these molecules indicates its potential role in resisting infection and COVID-19 disease progression. This review focuses on the potential role of algal nutraceuticals as immune boosters to combat the human coronavirus and other viral diseases. The potential use of Spirulina-based nutraceuticals for combating COVID-19, its mechanism, and future directions have also been discussed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680017 | PMC |
http://dx.doi.org/10.1016/j.nut.2020.111089 | DOI Listing |
Alzheimers Dement
December 2024
Brain Institute of Rio Grande Do Sul, PUCRS, Porto Alegre, RS, Brazil.
Background: Long COVID is an under-characterized disorder that affects a wide range of individuals after COVID-19 resolution. Long COVID individuals report persistent neurological manifestations, such as anxiety. Understanding its effects in the brain might help uncover the actual burden imposed by the pandemic sequelae and either define or discard long COVID as a risk factor for neurodegenerative diseases.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.
Background: The WHO's Global Dementia Action Plan comprises seven action areas, including dementia diagnosis, treatment, care, and support. Palliative care is called for as a core component of the care continuum from the diagnosis to the end of life. Japan has pursued a holistic care approach in dementia policies.
View Article and Find Full Text PDFBackground: Amidst the global impact of COVID-19, this study delves into how restrictions and positive interactions shape children's mental images of the elderly and dementia. We organized drawing sessions with three groups to investigate the malleability of children's perceptions, offering crucial insights for future Alzheimer's research.
Method: This study gathered 848 children's drawings from 106 ten-year-old children in Flanders and the Netherlands.
Alzheimers Dement
December 2024
National Center for Health Statistics, Hyattsville, MD, USA.
Background: Dementia-related mortality increased significantly in the first year of the COVID-19 pandemic in the United States. Explanations for the rise in dementia-related death rates are complex and multi-factorial. Older adults with dementia often have other chronic conditions that result in increased risk of death.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Background: Post-Covid syndrome is related to functional, cognitive, psychological and physical impairments in older adults, which has been associated with caregiver burden.
Method: Cross-sectional study nested within a prospective cohort, which recruited participants aged 60 and over, and their respective caregivers, twelve months after laboratory diagnosis of Covid-19. The project was approved by UFMG's ethics committee.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!